タンパク尿治療法の世界市場予測・分析2019-2023

◆英語タイトル:Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023
◆商品コード:IRTNTR32169
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年10月31日
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、タンパク尿治療法の世界市場について調べ、タンパク尿治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、タンパク尿治療法の市場規模をセグメンテーション別(製品別(ACE阻害薬、ARB、その他の治療薬)、)と地域別(グローバル)に分けて算出しました。Technavio社はタンパク尿治療法の世界市場規模が2019-2023期間中に年平均3%成長すると予測しています。
・サマリー
・レポートの範囲
・タンパク尿治療法の市場状況
・タンパク尿治療法の市場規模
・タンパク尿治療法の市場予測
・タンパク尿治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(ACE阻害薬、ARB、その他の治療薬)
・タンパク尿治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Proteinuria Therapeutics Market: About this market
Technavio’s proteinuria therapeutics market analysis considers sales from ACE inhibitors, ARBs, and other therapeutic products. Our analysis also considers the sales of proteinuria therapeutics in Asia, Europe, North America, and ROW. In 2018, the ACE inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of an enzyme in the body from producing angiotensin II, which narrows the blood vessels will play a significant role in the ACE inhibitors segment to maintain its market position. Also, our global proteinuria therapeutics market report looks at factors such as recent approvals and launch of advanced urinalysis diagnostic kits, increasing prevalence of associated risk factors, and growing geriatric population. However, lack of curative therapies, adverse effects of available therapeutics, and stringent regulations may hamper the growth of the proteinuria therapeutics industry over the forecast period.

Global Proteinuria Therapeutics Market: Overview
Increasing prevalence of associated risk factors
Proteinuria is a condition in which urine contains an abnormal amount of protein. This condition can be a sign of damage within the kidneys and CKD: the latter can result from diabetes as well as high blood pressure hypertension. Proteinuria can be caused by diseases that do not involve the kidneys, such as multiple myeloma and others, such as, AIDS, lupus, and rheumatoid arthritis, which also cause inflammation in the kidneys. Globally, the prevalence of all these diseases and infections is very high and is increasing continuously. This multifactorial etiology of the condition increases the demand for treatment options and, thus, drives the growth of the market at a CAGR of almost 3% during the forecast period.

Introduction of smartphone-based diagnosis and treatment
Advances in technology help in increasing the adherence of patients to treatment and, thus, obtain effective and quick results. They help in improving the condition of patients in less time. With the recent advances in technology and the proliferation of smartphone-based applications: urinalysis is also providing effective and quick results at a lower cost. Smartphone-based applications are unique as they are autonomous and do not need a specialist to make clinical decisions. Also, changing lifestyles and technological developments are encouraging more people to opt for application-based treatment due to its easy access. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global proteinuria therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global proteinuria therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteinuria therapeutics manufacturers, that include AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the proteinuria therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• ACE inhibitors – Market size and forecast 2018-2023
• ARBs – Market size and forecast 2018-2023
• Other therapeutics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Introduction of smartphone-based diagnosis and treatment.
• Advent of novel therapies
• Increasing awareness about renal disorders
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: ACE inhibitors – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: ACE inhibitors – Year-over-year growth 2019-2023 (%)
Exhibit 22: ARBs – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: ARBs – Year-over-year growth 2019-2023 (%)
Exhibit 24: Other therapeutics – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other therapeutics – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of the total population)
Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Prevalence/incidence of associated risk factors of proteinuria
Exhibit 46: Growth of geriatric population 2009-2018 (%)
Exhibit 47: Side effects of ACE inhibitors used for the treatment of proteinuria
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AbbVie Inc. – Vendor overview
Exhibit 55: AbbVie Inc. – Business segments
Exhibit 56: AbbVie Inc. – Organizational developments
Exhibit 57: AbbVie Inc. – Geographic focus
Exhibit 58: AbbVie Inc. – Key offerings
Exhibit 59: AbbVie Inc. – Key customers
Exhibit 60: AstraZeneca Plc – Vendor overview
Exhibit 61: AstraZeneca Plc – Business segments
Exhibit 62: AstraZeneca Plc – Organizational developments
Exhibit 63: AstraZeneca Plc – Geographic focus
Exhibit 64: AstraZeneca Plc – Key offerings
Exhibit 65: AstraZeneca Plc – Key customers
Exhibit 66: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 67: Boehringer Ingelheim International GmbH – Business segments
Exhibit 68: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 69: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 70: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 71: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 72: Boehringer Ingelheim International GmbH – Key customers
Exhibit 73: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 74: Bristol-Myers Squibb Co. – Business segments
Exhibit 75: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 76: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 77: Bristol-Myers Squibb Co. – Key offerings
Exhibit 78: Bristol-Myers Squibb Co. – Key customers
Exhibit 79: Merck & Co. Inc. – Vendor overview
Exhibit 80: Merck & Co. Inc. – Business segments
Exhibit 81: Merck & Co. Inc. – Organizational developments
Exhibit 82: Merck & Co. Inc. – Geographic focus
Exhibit 83: Merck & Co. Inc. – Segment focus
Exhibit 84: Merck & Co. Inc. – Key offerings
Exhibit 85: Merck & Co. Inc. – Key customers
Exhibit 86: Novartis AG – Vendor overview
Exhibit 87: Novartis AG – Business segments
Exhibit 88: Novartis AG – Organizational developments
Exhibit 89: Novartis AG – Geographic focus
Exhibit 90: Novartis AG – Segment focus
Exhibit 91: Novartis AG – Key offerings
Exhibit 92: Novartis AG – Key customers
Exhibit 93: Pfizer Inc. – Vendor overview
Exhibit 94: Pfizer Inc. – Business segments
Exhibit 95: Pfizer Inc. – Organizational developments
Exhibit 96: Pfizer Inc. – Geographic focus
Exhibit 97: Pfizer Inc. – Segment focus
Exhibit 98: Pfizer Inc. – Key offerings
Exhibit 99: Pfizer Inc. – Key customers
Exhibit 100: Sanofi – Vendor overview
Exhibit 101: Sanofi – Business segments
Exhibit 102: Sanofi – Organizational developments
Exhibit 103: Sanofi – Geographic focus
Exhibit 104: Sanofi – Segment focus
Exhibit 105: Sanofi – Key offerings
Exhibit 106: Sanofi – Key customers
Exhibit 107: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 108: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 115: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 116: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 117: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 118: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[タンパク尿治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆